Mike Nesbitt, in his role as Northern Ireland's health minister, spoke at the Stormont Assembly chamber this week.

The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult ...

Even light-intensity activities such as walking can reduce one’s risk for clinical depression. So, what are the most common ...

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...

The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression.

Blue Monday originated from a publicity stunt, but seasonal affective disorder is a real affliction that affects millions of ...

The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used ...

Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.

Part of you is concerned — after all, you know depression can be serious — but on the other hand, can’t weight loss be a good ...

Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression for those ...

The TGA has issued a requirement for new warnings to be provided with the drug montelukast, commonly used to treat asthma and ...

Johnson & Johnson has announced that the U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal ...